Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development.
Mario RienzoTomasz SkireckiGuillaume MonneretJean François TimsitPublished in: Expert opinion on investigational drugs (2022)
Preclinical results are positive and the first human early phase clinical trials showed a beneficial effect on immunological functions and/or markers and suggested that tolerance of CPIs side effects, mainly auto-immune disorders, is acceptable in sepsis. Elsewhere, in some specific severe ICU infections such as fungal infections, preliminary convincing case reports have been published. Overall, the first results regarding CPIs in sepsis appear encouraging. However, further efforts are warranted, especially in defining the right patients to be treated (i.e. in an individualized approach) and establishing the optimal time to start an immune restoration. Larger trials are now mandatory to confirm CPIs' potential in sepsis.
Keyphrases
- intensive care unit
- septic shock
- acute kidney injury
- clinical trial
- end stage renal disease
- newly diagnosed
- endothelial cells
- chronic kidney disease
- prognostic factors
- mechanical ventilation
- quality improvement
- case report
- human health
- acute respiratory distress syndrome
- mesenchymal stem cells
- bone marrow
- climate change
- extracorporeal membrane oxygenation
- study protocol
- patient reported
- induced pluripotent stem cells
- drug induced